Treatment Of Children With Short Stature At An Age Of 3-7 Years Who Were Born Small For Gestational Age
Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The primary objective is to evaluate, if Genotonorm (Genotropin) increases linear growth in
short children born SGA. Safety of the drug is a main objective as well. The growth promoting
effect of two different dosages is compared. The effect of long-term treatment on final
height is evaluated (according to several amendments)